They randomly assigned 702 patients with high-risk, muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every three weeks for a ...

They randomly assigned 702 patients with high-risk, muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every three weeks for a ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free ...

If you or a loved one is navigating an advanced bladder cancer diagnosis, visit PADCEV.com† to learn more about Armando and Laura's story and discover more about PADCEV with pembrolizumab as a ...

Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates ...

New treatments reshape metastatic and muscle-invasive bladder cancer therapy. ... So now most patients in the frontline metastatic setting will get [the] EV and pembrolizumab combination, ...

Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: hint of major added benefit. Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new drug ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

Video > Bladder Cancer Video Pearls Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer — And nearly half of responders to enfortumab vedotin plus pembrolizumab remained in remission ...

Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free ...